Skip to main content
logo
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.2639
+0.0039 (1.50%)
Aug 27, 2026, 11:37 AM EDT - Market open

Vistagen Therapeutics Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
2.51.270.491.06-0.231.11
Revenue Growth
287.15%161.11%-54.32%--1.78%
Gross Profit
2.51.270.491.06-0.231.11
Operating Income
-69.67-72.13-55.97-33.02-59.27-47.78
Net Income
-67.62-69.69-51.42-29.36-59.25-48.71
Earnings Per Share
-1.66-1.83-1.67-1.52-8.51-7.38
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
31.7345.480.48119.1716.6468.14
Total Debt
0.781.041.512.122.713.04
Net Cash (Debt)
30.9544.3678.97117.0513.9365.1
Net Cash Growth
-49.12%-43.83%-32.53%740.43%-78.61%-34.50%
Net Cash Per Share
0.761.172.566.052.009.86

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-62.3-66.44-42.1-25.81-49.72-45.26
Capital Expenditures
-0.09-0.15-0.19-0.06-0.21-0.2
Free Cash Flow
-62.38-66.59-42.29-25.87-49.93-45.46
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
100.00%100.00%100.00%100.00%-100.00%
Operating Margin
-2785.69%-5683.69%-11517.08%-3103.48%--4308.68%
Pretax Margin
-2703.44%-5490.78%-10578.40%-2759.21%26097.80%-4306.88%
Profit Margin
-2703.72%-5491.33%-10579.83%-2759.59%--4392.42%
FCF Margin
-2494.32%-5247.20%-8701.24%-2431.77%--4099.28%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
4.7417.84148.47134.11-120.48230.95